1. 0.0-Home
2. 1.0-Efficacy-OS
3. 1.1-Efficacy-CR_CRh
4. 1.2-Hematologic-parameters
5. 1.3-Transfusion-independence
6. 1.4-EFS
7. 1.5-Safety
8. 10.0-Safety
9. 11.0-Dosing
10. 12.0-IDH1
11. 12.1-IDH1-MOA
12. 13.0-NCCN
13. 14.0-MDS_AML
14. 14.1-MDS_AML-GENETIC_ABNORMALITIES
15. 15.0-Summary
16. 2.0-Efficacy-CR_CRh
17. 2.1-Duration-of-response
18. 2.2-Time-to-response
19. 2.3-Hematologic-parameters
20. 2.4-Transfusion-independence
21. 2.5-Safety
22. 3.0-Efficacy-CR-and_or-CRh
23. 3.1-Duration-of-response
24. 3.2-Time-to-response
25. 3.3-Transfusion-independence
26. 3.4-OS
27. 3.5-Hematologic-parameters
28. 3.6-Safety
29. 4.0-Dosing-regimen
30. 4.1-Dosing-guidance
31. 5.0-IDH1
32. 5.1-MoA
33. 5.1-TESTING
34. 5.2-MoA
35. 5.2-TESTING
36. 6.0-GUIDELINES
37. 7.0-INDICATIONS-SUMMARY
38. 8.0-Home
39. 9.0-Efficacy-UNMET_NEED
40. 9.1-Efficacy-REMISSION
41. 9.2-Efficacy-TRANSFUSION_INDEPENDENCE
42. 9.3-Efficacy-TIME_TO_RESPONSE
43. 9.4-Efficacy-OVERALL_SURVIVAL